Piper Sandler raised the firm’s price target on Madrigal Pharmaceuticals to $336 from $305 and keeps an Overweight rating on the shares. The firm remains bullish on Madrigal, especially with resmetirom’s March 14 PDUFA imminently approaching. Altogether, Piper is confident in approval and thus sees a buying opportunity into this key stock moving event to support its new price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MDGL:
- Madrigal Pharmaceuticals reports inducement grants under Nasdaq listing rule
- Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- 3 Best Stocks to Buy Now, 1/19/2024, According to Top Analysts
- Madrigal Pharmaceuticals presents five health economics outcomes abstracts
- Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG Annual Conference
